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Background/aim: This study was undertaken to identify subjects with human immunodeficiency virus and tuberculosis (HIV/TB)
coinfection in a group of HIV-positive patients followed at five different healthcare centers, and to determine the demographic and
clinical characteristics of these subjects as well as the predictors of mortality.
Materials and methods: A database search for subjects with TB coinfection was performed among 1475 HIV-positive adult patients and
a total of 66 individuals were identified with HIV/TB coinfection.
Results: There were 66 patients (4.5%) with TB coinfection. Twenty-one percent (n = 14) of the patients with TB coinfection died
during the study period and these patients had significantly lower baseline CD4 counts at the time of TB diagnosis (P = 0.005). None
of the patients with CD4 count of ≥200 cells/mm3 died during follow-up and a low CD4 count at the time of TB diagnosis (<200 cells/
mm3) was associated with poor survival (P = 0.012). However, none of the parameters emerged as significant independent predictors
of survival in multivariate analysis.
Conclusion: Coexistence of TB and HIV infection is associated with many clinical challenges and a better understanding of patient
characteristics as well as the parameters impacting the outcome will improve the quality of care provided for this group of patients.
Key words: Human immunodeficiency virus, tuberculosis, coinfection, mortality

1. Introduction
Human immunodeficiency virus (HIV) infection
is associated with deterioration of cellular immune
responses and increased risk of opportunistic infections
via reduced CD4+ T lymphocyte count. According to
the data provided by the World Health Organization,
the global number of HIV-positive individuals reached
36.9 million in 2014 (http://www.who.int/hiv/data/epi_
core_july2015.png?ua=1). Tuberculosis (TB) represents
the second leading cause of mortality from infectious
diseases following HIV infection. Furthermore, TB is the
most common opportunistic infection in HIV-positive
individuals and is a major cause of death (1).
TB prevalence in Turkey was estimated to be 21/100,000
in the general population in 2011 and its incidence has
* Correspondence: fatmasargin2002@yahoo.com

been decreasing over the years (2). The prevalence of TB in
the largest city, İstanbul, was slightly higher (36/100,000)
than in the general population (2).
HIV infection is an important risk factor for the rapid
development of TB after exposure (3–6) and HIV-positive
subjects have an increased risk of reactivation of latent TB
and active TB (7). Active treatment of latent TB infections
carries clinical significance with respect to decreasing the
TB-associated morbidity and mortality and reducing the
risk of TB transmission (8,9).
In addition, active TB infection leads to a significantly
increased HIV viral number (10), and TB has a negative
impact on the course of HIV infection, leading to the
development of acquired immune deficiency syndrome
(AIDS), accelerated disease progression, and death
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(11,12). According to the 2014 Global Tuberculosis Report
of the World Health Organization, among 9 million cases
of TB diagnosed in the previous year, HIV was present
in 1.1 million and of the 1.5 million deaths due to TB,
360,000 were HIV-positive individuals (http://apps.who.
int/iris/bitstream/10665/191102/1/9789241565059_eng.
pdf?ua=1).
Although antiretroviral therapy (ART) leads to
a dramatic drop in morbidity and mortality in TB/
HIV coinfection, simultaneous administration of
antiretroviral and antituberculous treatments may give
rise to complications such as drug interactions, toxicity,
or worsening of TB symptoms due to HIV/TB-associated
immune reconstitution inflammatory syndrome (13).
Thus TB/HIV coinfection requires a complex approach.
To date, only a few studies examined patients with
HIV/TB coinfection or provided data on this condition
in Turkey (14–16). This study was undertaken to
identify subjects with HIV/TB coinfection in a group of
HIV-positive patients followed at five different tertiary
healthcare centers, and to determine the demographic
and clinical characteristics of those subjects as well as the
predictors of mortality.
2. Materials and methods
2.1. Patients
The database of the ACTHIVIST group was used for
the study purposes. This group was established by the
participation of 5 tertiary care institutions (3 university
hospitals and 2 research and training hospitals) that
maintain a registry of HIV-positive patients in İstanbul,
a large metropolitan city with a high number of HIVpositive residents. The medical data of HIV-positive
patients followed by the centers mentioned above are
entered into a joint database. The study was conducted in
accordance with the Declaration of Helsinki and relevant
laws and guidelines, and the study protocol was approved
by the local ethics committee (no. 2015/0065, dated 27
May 2015).
Among a group of 1475 HIV-positive adult patients
(>18 years) with data entry between 1996 and 2015,
those diagnosed with active TB based on clinical,
microbiological, histopathological, or imaging studies any
time during the specified time period were included in
this study. All data were transferred to Excel files and were
sent to the respective centers for data update, following
the addition of extra columns to these files for missing
information required for study analyses. The missing data
were completed by each center using the information
gathered from patient records, through telephone contact
with the patient, or from the hospital database. Completed
and updated data were used for statistical analyses. HIVpositive patients with no proper patient file or missing
major data were excluded.
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Age, gender, race, sexual identity, baseline CD4 T cell
count and HIV RNA (at the time TB was diagnosed),
timing of TB with respect to ART, mortality status, and the
localization of TB (pulmonary vs. extrapulmonary) were
recorded and assessed.
2.2. Statistical analysis
Study data were analyzed using the SPSS 21 for Windows
(IBM Corp., Armonk, NY, USA). Categorical data were
compared with Fischer’s exact test, while the Mann–
Whitney U test was used for continuous variables.
Univariate comparisons for survival were done using the
log-rank test. Survival was defined as the time elapsed
between the diagnosis of TB and death from any cause,
and patients alive at the last follow-up were censored.
Potential predictors of survival were entered into a Cox
proportional hazards model to identify independent
predictors of mortality. Two-sided P-values of <0.05 were
considered statistically significant.
3. Results
Within the total cohort of 1475 patients, TB was detected
in 66 (4.5%). The Table shows the characteristics of HIVpositive patients with TB coinfection. More than twothirds of the patients had a CD4 T lymphocyte count
of less than 200 cells/mm3 at the time of TB diagnosis
and about a quarter had less than 50 cells/mm3. In the
majority of patients, HIV infection was presented with TB
infection (72.7%). In only 12.1% of cases, TB developed
when the patient was receiving ART. Forty-one patients
(62%) had pulmonary and 25 (38%) had extrapulmonary
TB. At least one comorbid condition was present in
18 patients (27.3%): hepatitis B virus infection (n = 3),
cytomegalovirus infection (n = 3), Pneumocystis jirovecii
pneumonia (n = 2), Kaposi’s sarcoma (n = 2), syphilis
(n = 2), esophageal candidiasis (n = 1), cryptococcal
meningitis (n = 1), cerebral toxoplasmosis (n = 1), HIV
encephalopathy (n = 1), psychosis (n = 2), depression (n =
1), coronary artery disease (n = 1), and chronic obstructive
pulmonary disease (n = 1). Twenty-one percent (n = 14) of
the patients with TB coinfection died during follow-up. A
higher proportion of patients who died during follow-up
had their HIV infection presenting with TB compared to
those who developed TB after being diagnosed with HIV
(93% vs. 65%, P = 0.040).
The mean survival of patients with coinfection was
191 ± 17 months (95% CI: 157–225 months). In univariate
analysis with the log-rank test, age group (>40 vs. ≤40) (P
= 0.443), gender (P = 0.939), sexual identity (P = 0.706),
presence of comorbidity (P = 0.998), HIV RNA at the time
of TB diagnosis (<100,000 vs. ≥100,000 copies/mL) (P =
0.753), presence of extrapulmonary TB (P = 0.249), race
(P = 0.051), and presentation of HIV with TB (P = 0.062)
did not have a significant effect on survival. However, a
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Table. Patient characteristics (n = 66).
Age1, years (mean ± SD)

38.7 ± 9.2

Male gender

57 (86.4%)

Race
Caucasian

64 (97.0%)

Black

2 (3.0%)

Sexual identity
Heterosexual

38 (57.6%)

Homosexual

12 (18.2%)

Bisexual

6 (9.1%)

Not specified

10 (15.2%)

Comorbidity present

18 (27.3%)

CD4 cell count1 (cells/mm3)
≤50

16 (24.2%)

>50; ≤200

30 (45.5%)

>200

20 (30.3%)

HIV RNA1 (copies/mL)
<100,000

45 (68.2%)

≥100,000

11 (16.7%)

Data not available

10 (15.2%)

Extrapulmonary tuberculosis

25 (37.9%)

Timing of HIV, TB, and ART
HIV presented with TB

48 (72.7%)

TB developed without ART

10 (15.2%)

TB developed under ART

8 (12.1%)

Death during follow-up2

14 (21.2%)

Unless otherwise stated, data are presented as n (%). 1At the
time of TB diagnosis, 2long-term follow-up data available for 60
patients.
SD, Standard deviation; CD4, cluster of differentiation 4; HIV,
human immunodeficiency virus; RNA, ribonucleic acid; TB,
tuberculosis; ART, antiretroviral therapy.

low CD4 T cell count at the time of TB diagnosis (<200
cells/mm3) was associated with poor survival (P = 0.012).
In addition, patients who died during follow-up had
significantly lower CD4 T cell counts at the time of TB
diagnosis compared to those who survived (66 ± 44 vs.
194 ± 169, P = 0.005). Although none of the patients with
CD4 T cell count of ≥200 cells/mm3 died during followup, survival statistics could not be computed since all cases

were censored. None of the parameters were identified as
independent significant predictors of survival in the Cox
proportional hazard model.
4. Discussion
Based on recent reports, there were about 8200 HIVpositive individuals in Turkey by mid-2014 (http://www.
hatam.hacettepe.edu.tr/veriler_Haziran_2014.pdf). Thus,
our cohort represents nearly 15% of all HIV-positive cases
in Turkey. To date, data on HIV/TB coinfection in Turkey
have been very limited and have mostly been dependent
on official figures based on notifications and on a few
publications (14–17).
In this study, the prevalence rate of TB among
HIV-positive individuals was 4.5%. According to the
2015 Global Tuberculosis Report of the World Health
Organization, 1.2 million out of the 9.6 million global
cases of TB (12%) were HIV-positive (http://apps.who.
int/iris/bitstream/10665/191102/1/9789241565059_eng.
pdf?ua=1). In the same document, 9344 of the total 13,378
reported cases of TB from Turkey were reported to have
a “known status” of HIV serology, with 45 cases (0.48%)
being HIV-positive. Similarly, the most recent national
report on TB reported an HIV positivity rate of 0.31%
among individuals with TB for whom HIV test results were
available (17). However, these data are based on official
notifications. In a metaanalysis by Gao et al., 0.9% of TB
patients were reported to have HIV coinfection, while
the prevalence of TB among HIV-positive subjects was
7.2% (18). In another metaanalysis by the same authors,
the coinfection prevalence for these two conditions in
countries other than China was found to vary between
2.9% and 72.3%, with an average prevalence rate of 23.5%
(19). The specific figures for geographic locations including
African, Asian, European, and Latin America countries
were 31.25%, 17.21%, 20.11%, and 25.06%, respectively,
while a prevalence of 14.8% was reported for the United
States (19). However, in that metaanalysis, studies looking
at HIV positivity in patients with TB and those looking at
TB coinfection in HIV-positive patients were considered
jointly, with generally close figures for these two subset
of individuals (19). A study from Turkey investigated
mycobacterial infections among 383 HIV-infected patients
and found mycobacterial infection in 6%, most of them
being Mycobacterium tuberculosis infections (19 out of 24)
(14). In another Turkish study, TB was the most common
opportunistic infection (16.5%) among 115 HIV-positive
individuals (15). On the contrary, TB was the third most
frequent opportunistic infection (4%), preceded by oral
candidiasis (15%) and P. jirovecii pneumonia (8%), in a
study from the Cappadocia region of Turkey (16).
An HIV positivity rate of 0.31%–0.48% among
TB patients in Turkey is relatively low. In addition,
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coexistence of TB in 4.5% of the HIV-positive patients in
this study is relatively lower than those studies from the
world mentioned above and several studies from Turkey
(14,15). While this may partly be explained by the lower
prevalence of HIV as well as the lower and decreasing
prevalence and burden of TB in Turkey (2,17,20), the low
rate of HIV testing among TB patients, the common use
of tuberculin skin testing and the use of prophylaxis for
latent TB among HIV-positive individuals, and the unique
profile of the İstanbul cohort (i.e. higher socioeconomic
level, better healthcare access, better healthcare after
diagnosis including earlier initiation of ART) might all
have contributed to this relatively low frequency among
our patients.
Low CD4 T cell counts were associated with a high
risk of TB in a number of studies, with calculated relative
risks of 15.7 and 3.2 for cell counts below 200 and between
200 and 350, respectively (21–23). Low CD4 T cell count
was also associated with mortality (21), with a CD4 count
below 200 cells/µL resulting in increased mortality (24).
Similarly, in our study, those who survived had significantly
higher CD4 T cell counts than those who died.
The mortality rate of 21% among our patients with HIV/
TB coinfection is higher than that (12%) reported by Chu
et al. in Uganda (25). In the metaanalysis of Straetemans
et al., the all-cause mortality with TB coinfection was
2-fold higher as compared to that without TB coinfection,
although in a subgroup analysis involving higher use of
highly active ART, non-TB factors rather than TB were
found to play a role in mortality, and no increased risk
of mortality was observed for those patients with TB
coinfection compared to those without (26). In another
study including individuals with easy access to ART, TB
coinfection was associated with a 4.5-fold increased risk of
all-cause mortality (27). Considering the high number of
cases (2/3) with a low CD4 T cell count in our study and
the significant association between CD4 T cell count and
mortality, the high mortality rate is not surprising.
A high mortality rate in our TB/HIV coinfected patients
and a lower baseline CD4 count in patients who died
suggest a delay in the diagnosis of coinfection. Another
reason for high mortality may be that the majority of the
patients were not on ART at the time of TB diagnosis
(either HIV patients presented with TB infection or were
not receiving ART at the time of TB diagnosis).
Although the results of our study are consistent with
previous reports in terms of increased mortality (21,24),
this did not emerge as an independent predictor of
mortality, probably due to the small sample size.
The predominance of male patients in the subgroup
of patients with TB coinfection as in the overall cohort
is consistent with many reports from different areas of
Sub-Saharan Africa, where TB is highly endemic (21–23),

506

and in the TB/HIV Rio (ThRIo) cohort from Brazil (21).
In 2011, of the newly diagnosed cases of TB in Turkey,
58.6% and 41.4% were male and female, respectively
(http://tuberkuloz.thsk.saglik.gov.tr/Dosya/Dokumanlar/
raporlar/turkiyede_verem_savasi_2013_raporu.pdf). The
gender distribution in our group with HIV/TB coinfection
more closely resembles the HIV-positive patients rather
than the overall population of TB patients in Turkey. It is
not surprising to observe a higher predominance of male
patients with HBV/TB coinfection in a larger sample set
with male predominance.
In a 2012 metaanalysis, a strong link between HIV
infection and extrapulmonary TB was found, while a
CD4 T cell count of less than 100 cells/µL was suggested
to represent a significant factor for the development of
extrapulmonary TB in a subgroup analysis (24).
Although pulmonary TB is the most common form
of disease presentation irrespective of the stage of HIV
infection, extrapulmonary TB occurs at a higher frequency
among severely immunocompromised individuals as
compared to HIV-negative individuals or HIV-positive
individuals with intact immunity (28). In the present
study, 62% and 38% of the patients had pulmonary and
extrapulmonary TB, consistent with the overall figures from
Turkey, where 59.3%, 36.8%, and 3.9% of the reported cases
of TB had pulmonary, extrapulmonary, and both types of
involvement, respectively (http://tuberkuloz.thsk.saglik.
gov.tr/Dosya/Dokumanlar/raporlar/turkiyede_verem_
savasi_2013_raporu.pdf). In other words, our observation
is at odds with the expected increase in the occurrence of
extrapulmonary TB in HIV-positive patients.
On the other hand, despite the numerically higher
mortality among those with extrapulmonary TB (63% vs.
34%), the difference was not significant, probably due to
the small sample size.
One limitation of our study is its small sample size.
Most parameters did not reach significance for predicting
mortality, which may be due to type II error caused by
small sample size. Second, since a retrospective evaluation
was performed on patient records with data entry prior
to the study, missing data including data on treatments
could not be completed in some patients. Third, this
cohort represents the largest metropole of Turkey and
patient characteristics may be different from those from
other locations of the country and thus findings may not
be generalized.
In conclusion, TB has always been an important
infectious disease both globally and in Turkey, whereas the
origination of HIV dates back to more recent times and HIV
is a relatively new disease entity for Turkey. Cooccurrence
of these two conditions is associated with a number of
problems such as the coinciding adverse consequences,
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multidrug use, drug toxicity, and drug resistance. In this
cohort, the patient characteristics of individuals with TB/
HIV coinfection were reviewed in order to shed light on

the overall status of such patients. Early diagnosis and
treatment of HIV infection and TB carry great significance
both for society and for individuals.
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